EyeDNA's HORA-PDE6b Receives FDA Rare Pediatric Disease Designation for PDE6b Retinitis Pigmentosa
EyeDNA Therapeutics' HORA-PDE6b, a novel gene therapy, has received Rare Pediatric Disease Designation from the FDA for PDE6b-related retinitis pigmentosa.
© Copyright 2025. All Rights Reserved by MedPath